About Doctor
🩺 Medical Oncologist
Dr. Sachin V. Trivedi
Director – Medical Oncology, HCG Cancer Centre, Mumbai
MBBS
MRCP (London)
CCST (Med Onc)
SCE
FRCP (Edin)
PhD
An internationally trained and highly experienced Medical Oncologist with over a decade of expertise in managing solid tumours and providing evidence-based cancer care. Having worked across the UK and India, committed to advancing oncology services and delivering patient-centred treatment with compassion and precision.
👨⚕️ About the Doctor
Dr. Sachin V. Trivedi currently serves as the Director of Medical Oncology at HCG Cancer Centre, Mumbai. With extensive international experience, including his tenure as the Head of Oncology Services at Nottingham University Hospitals (UK), Dr. Trivedi brings a global perspective to cancer care in India.
He has been deeply involved in teaching, clinical research, and mentoring future oncologists. His clinical expertise covers a wide range of solid tumours, and he is recognized for developing efficient oncology service models and leading multidisciplinary teams.
Driven by a mission to make advanced oncology care accessible, Dr. Trivedi combines his academic excellence with compassionate care for every patient.
🎓 Qualifications
FRCP (Edinburgh)
Royal College of Physicians, Edinburgh
SCE (Medical Oncology)
Royal College of Physicians, UK
PhD
Charles University, Prague
MRCP (London)
Royal College of Physicians, London
MBBS
Nagpur University, India
ECFMG Certification
USMLE Board, USA
Professional Experience
Director – Medical Oncology
HCG Cancer Centre, Mumbai
2023 – Present
Head of Oncology Services
Nottingham University Hospitals, UK
2018 – 2023
Oncology Fellow
Royal Marsden Hospital, London
2013 – 2014
Medical Oncology Training
West Midlands Deanery, UK
General Internal Medicine Training
London
Led large clinical teams, established oncology service pathways, and supervised several oncology trainees who now serve as consultants in the UK.
🔬 Research & Publications
Dr. Trivedi has conducted extensive research in the use of Neopterin as a biomarker of immune activation in oncology and has authored multiple international research papers in peer-reviewed journals. He has served as Principal Investigator (PI) and Sub-Investigator for numerous national and international clinical trials, contributing to the advancement of cancer therapeutics and personalized medicine.
Professional Memberships